V01547 31 D/30.6 P 4.1 D/4.37 P APH(3')-IV Km, Neo, Prm, Rsm, But aph(3')-IVa aphA4 X01986 28.5 D/29.9 P 4.8 APH(3')-V Neo, Prm, Rsm aph(3')-Va aphA-Sa K00432 32 D/30.0 P 4.46 aph(3')-Vb aphA-Sb, rph M22126 29.5 P 4.5 AACG3i-Ia AAC (3)-lb AACi3ili1a AAC(3)-lic AAC(3)-lib AAC(3)-VIa AAC(3)-Vila AACI3)-Xa AAC(3)-l Xa AAC(3)-VIlia AAC(3)-lilb AACi3)-11Ic AACi3-ilia AACi3)-IVa AAC(3 la AAC(3)-lb AAC(3)-ila AAC(3)-Iic AAC(3)-ilb AAC(3)-Via AAC(3)-Vlla AAC(3)-Xa AAC(3)-iXa AAC(3)-Viiia AAC(3)-iiib AAC(3i-lIIc AAC(3)-illa AAC'.3)-iVa AAC(3)-la AACi 3)-lb AAC(3)-iia AAC(3)-1ic AAC(3)-iib AAC(3)-Vla AAC(3)-Viia

The contribution of seven known and nine predicted genes or operons associated with multidrug resistance to the susceptibility of Escherichia coli W3110 was assessed for 20 different classes of antimicrobial compounds that include antibiotics, antiseptics, detergents, and dyes. Strains were constructed with deletions for genes in the major facilitator superfamily, the resistance nodulation-cell division family, the small multidrug resistance family, the ATP-binding cassette family, and outer membrane factors. The agar dilution MICs of 35 compounds were determined for strains with deletions for multidrug resistance (MDR) pumps. Deletions in acrAB or tolC resulted in increased susceptibilities to the majority of compounds tested. The remaining MDR pump gene deletions resulted in increased susceptibilities to far fewer compounds. The results identify which MDR pumps contribute to intrinsic resistance under the conditions tested and supply practical information useful for designing sensitive assay strains for cell-based screening of antibacterial compounds.

No abstract

The likelihood of reobstruction increases and the time to reobstruction decreases with increasing number of previous episodes of obstruction. Patients with matted adhesions have a greater recurrence rate than those with band adhesions. Non-operative treatment for adhesions in stable patients results in a shorter hospital stay and similar recurrence and reoperation rates, but a reduced interval to reobstruction when compared with operative treatment.